182 related articles for article (PubMed ID: 21599533)
21. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
Robson R; Buttimore A; Lynn K; Brewster M; Ward P
Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and renal toxicity of three once-a-day doses of amikacin in cows.
Sumano H; Gutierrez L; Velazquez C; Hayashida S
Acta Vet Hung; 2005; 53(2):231-40. PubMed ID: 15959981
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
Marbury T; Dowell JA; Seltzer E; Buckwalter M
J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
[TBL] [Abstract][Full Text] [Related]
26. A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.
Montgomery AB; Vallance S; Abuan T; Tservistas M; Davies A
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):441-8. PubMed ID: 24383962
[TBL] [Abstract][Full Text] [Related]
27. Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs.
KuKanich B; Coetzee JF
J Vet Pharmacol Ther; 2008 Apr; 31(2):102-7. PubMed ID: 18307501
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model.
Pouzot-Nevoret C; Magnin M; Ayoub JY; Bourguignon L; Maire P; Wertz D; Goy-Thollot I; Barthélemy A; Boselli E; Allaouchiche B; Bonnet-Garin JM
Int J Antimicrob Agents; 2017 Aug; 50(2):148-154. PubMed ID: 28689868
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
31. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
[TBL] [Abstract][Full Text] [Related]
32. Optimizing the initial amikacin dosage in adults.
White BP; Lomaestro B; Pai MP
Antimicrob Agents Chemother; 2015 Nov; 59(11):7094-6. PubMed ID: 26282426
[TBL] [Abstract][Full Text] [Related]
33. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
34. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy.
Taccone FS; de Backer D; Laterre PF; Spapen H; Dugernier T; Delattre I; Wallemacq P; Vincent JL; Jacobs F
Int J Antimicrob Agents; 2011 Jun; 37(6):531-5. PubMed ID: 21489756
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
[TBL] [Abstract][Full Text] [Related]
37. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia.
Luyt CE; Clavel M; Guntupalli K; Johannigman J; Kennedy JI; Wood C; Corkery K; Gribben D; Chastre J
Crit Care; 2009; 13(6):R200. PubMed ID: 20003269
[TBL] [Abstract][Full Text] [Related]
39. Effect of renal impairment on the pharmacokinetics of exenatide.
Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
[TBL] [Abstract][Full Text] [Related]
40. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
